Clinical Trial Search

Primary: The Eradication Rate of Helicobacter Pylori Infection — 18; 17; 5; 10 Participants

Primary: Combination Phase: Percentage of Participants Who Achieved Clinical Response at Week 12 — 61.1; 74.6; 83.1 Percentage of participants

Primary: Number of Participants With a Predicted Effect on αVβ6 PET ( Positron Emission Tomography) in Lungs After Administration of Drug. — 1; 1; 0; 2 Participants

Primary: Number of Participants Discontinuing Study Treatment Due to TEAEs — 1; 3; 4 Participants

Primary: Overall Hematologic Response Rate by 6 Months — 46.3 Percentage of participants

Primary: Primary Efficacy Endpoint: Change From Baseline in Visual Analog Scale (VAS) for Pain at 90 Days — 32.8; 34.1; -35.1; -34.2 score on a scale

Primary: Response Rate — 2; 13; 21; 1 Participants

Primary: Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24 — -20.93; 8.13; -18.33; 21.13 percent…

Primary: Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 8; 6; 13; 7 Participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2) — 8; 38 Participants

Primary: Relapse Free Survival (RFS) Rate at 32 Months — 50 Probability

Primary: Number of Participants Experiencing Regimen-limiting Toxicity (RLT) — 0; 0 Participants

Primary: Change From Baseline of Veterans RAND 36-Item Health Survey Physical Component Summary Score (PCS) Scores at 8 and 16 Weeks — 40.8; 41.5; 43.5; 43.4 units on a scale

Primary: Percentage of Participants Who Experience Acute GvHD — 38.46 percentage of participants

Primary: 4 Cycle Response Rate — 0.971 proportion of participants